American Heart Association (AHA)
7272 Greenville Avenue
608 articles about American Heart Association (AHA)
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease
Foresee Pharmaceuticals, announced that the company will be presenting at the American Heart Association 2023 Annual Meeting taking place in Philadelphia, PA, from November 11-13, 2023.
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
Amarin Corporation plc highlighted key data presented at the American Heart Association 2022 Scientific Sessions relevant to VASCEPA®/VAZKEPA and patient care.
Children's Hospital of Philadelphia Receives $400,000 Grant from American Heart Association to Study Hormones Related to Cardiovascular Disease and Metabolic Health
Children's Hospital of Philadelphia has received a $400,000 grant from the American Heart Association to help study heart-secreted hormones.
Lexicon Pharmaceuticals, Inc. welcomes new guidelines for the management of heart failure issued jointly this past weekend by the American Heart Association, the American College of Cardiology and the Heart Failure Society of America.
Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease
Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-year collaboration to accelerate education and awareness of heart disease.
According to CDC heart disease likely to remain No. 1 cause of death despite COVID-19. Comprehensive advanced primary care can help
According to the American Heart Association, heart disease and stroke continue to kill more people in the U.S. than any other cause, despite, and likely even linked to, the impact of the COVID-19 pandemic.
Three companies have posted major developments in the field of heart disease therapy.
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
Mesoblast Limited announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association class II and class III chronic heart failure with reduced ejection fraction were presented as a late breaking presentation at the American Heart Association annual Scientific Sessions during a featured program titled ‘Building on the Foundations of Treatment: Advances in Heart Failure Therapy’.
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced positive interim results from the ongoing Phase 1 study of zilebesiran, an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of hypertension.
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced the upcoming presentations of clinical and non-clinical data from its cardiovascular pipeline, including several of its investigational antisense medicines for cardiovascular disease, at the American Heart Association Scientific Sessions, to be held virtually Nov. 13-15, 2021.
HeartFlow Analysis is First AI-Enabled Technology to be Recognized by the American College of Cardiology and American Heart Association Guidelines as an Important Tool in Diagnosing and Treating Heart Disease
HeartFlow, Inc. welcomed new clinical practice guidelines from the American College of Cardiology and American Heart Association that recognized the HeartFlow FFRct Analysis with Class of Recommendation 2a, identifying it as an important tool for diagnosing coronary artery disease and guiding decision-making regarding the use of revascularization procedures such as coronary stenting or bypass surgery.
Scientists found recently that a naturally occurring protein from human umbilical cord blood might be the key to increasing survival and recovery rates in stroke patients.
Children's Hospital of Philadelphia-American Heart Association Collaboration Advances Efforts to Enhance Pediatric Resuscitation Programs in Philadelphia
Children's Hospital of Philadelphia and the American Heart Association have announced an enhanced collaboration to advance the next generation of pediatric emergency cardiovascular care and resuscitation practices.
The American College of Physicians, publisher of Annals of Internal Medicine, one of the most influential peer-reviewed clinical journals in the world, and the American Heart Association announce a new partnership to jointly publish Annals of Internal Medicine: Clinical Cases.
Women's History Month EmPOWERED to Serve™ roundtable focuses on challenges women continue to face in pursuit of health equity
American Heart Association announces EmPOWERED to Serve™ Black Women and Well-Being Roundtable in partnership with Divine Nine Sororities and The Links, Inc.
In the U.S., 50% of adults have high blood pressure, but only one out of four has it under control.1 Preventric Diagnostics is a digital health company that uses its BPro® wearable medical device to capture 24-hour ambulatory blood pressure and is incorporating American Heart Association science-based health management plans, called CarePlans, in its hypertension management platform.
New comprehensive book and digital resources from the American Heart Association; made possible by a gift from Pete and Brandy Nordstrom
American Heart Association Social Impact Fund financially supports innovative solutions to the challenges that have contributed to the disproportionate effect of COVID-19 in communities of color
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
Single doses resulted in potent, dose-dependent PCSK9 reductions of up to >90%, demonstrating best-in-class potential for the treatment of patients with high cholesterol at risk of cardiovascular disease